255:. No patients were harmed in the trial and patients in both groups lived longer than expected, with those being given lintuzumab having a lower death rate. However, the study found that there was no benefit to patients on a statistical basis, and that it did not reduce the risk of infection or the need for
246:
studied 211 individuals ages 60 and over who had been enrolled by
February 2009 and who were poor candidates for high-dose chemotherapy or had made the choice to reject the traditional chemotherapy treatment. The study participants typically had a projected four to five months to live, with half
371:"Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia"
223:
Lintuzumab had been in mid-stage clinical trial when
Seattle Genetics pulled the drug in September 2010 after evidence showed that it did not lead to higher survival rates. The U.S.
78:
157:
425:
350:
345:
284:
as Clolar that targets a different treatment approach, failed to get approval from the FDA in
October 2009, which said that additional trials were needed.
1415:
34:
834:
1410:
274:
that also targets the CD33 protein on leukemic cells, was withdrawn from the market in June 2010 after trials showed little benefit to patients.
1366:
1035:
1255:
418:
892:
819:
724:
749:
411:
734:
839:
178:
698:
224:
135:
1383:
477:
198:
193:(AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the
942:
228:
212:
324:
1371:
1338:
1279:
1230:
1145:
769:
239:, which had been unsuccessful in treating AML in clinical trials of its own in which they used lower doses.
1309:
1299:
1269:
1060:
1005:
932:
922:
799:
190:
235:
status for treatment of AML and myelodysplastic syndromes. Seattle
Genetics had licensed lintuzumab from
1420:
1284:
1273:
1235:
1125:
1110:
1040:
1020:
1015:
794:
548:
267:
1135:
995:
764:
729:
1250:
1220:
1215:
1200:
1030:
877:
829:
789:
434:
99:
44:
27:
488:
972:
523:
483:
329:
204:
Trials for AML were abandoned in 2010 when a phase IIb trial failed to show increased survival.
859:
678:
392:
256:
207:
As of 2010, Seattle
Genetics was conducting Phase II trials of lintuzumab in conjunction with
382:
369:
Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, et al. (June 2005).
186:
108:
144:
303:
1377:
1343:
1010:
243:
1404:
1225:
1080:
633:
468:
236:
1240:
1205:
1190:
1185:
1180:
1175:
1150:
1105:
1100:
1095:
1090:
1075:
962:
937:
917:
779:
744:
683:
663:
473:
458:
403:
1348:
1322:
1317:
1289:
1265:
1260:
1195:
1170:
1160:
1130:
1120:
1085:
1070:
1055:
1045:
1025:
1000:
985:
957:
907:
902:
897:
882:
872:
849:
844:
814:
759:
703:
693:
668:
658:
653:
648:
623:
598:
588:
583:
578:
568:
553:
538:
533:
518:
513:
503:
498:
493:
463:
277:
232:
1294:
1245:
1210:
1115:
1065:
1050:
990:
980:
952:
927:
867:
809:
804:
739:
719:
673:
643:
638:
628:
618:
613:
603:
593:
563:
558:
528:
508:
248:
208:
119:
1165:
1155:
947:
912:
887:
824:
784:
774:
754:
688:
608:
573:
543:
387:
370:
49:
396:
20:
443:
281:
252:
61:
271:
247:
treated with lintuzumab and a low dose of the chemotherapeutic agent
182:
251:, while the other half were given cytarabine in combination with a
346:"Disappointing Phase II Data Leads Seattle to Ditch AML Candidate"
53:
194:
66:
407:
164:
211:(marketed as Velcade) as a treatment for those with
201:, but does not appear in abundance on normal cells.
1331:
1308:
971:
858:
712:
451:
442:
134:
118:
98:
93:
77:
72:
60:
43:
33:
26:
306:, Seattle Genetics. Accessed September 13, 2010.
107:
419:
197:protein, which is expressed in AML and other
8:
351:Genetic Engineering & Biotechnology News
270:(marketed as Mylotarg), a similar drug from
19:
448:
426:
412:
404:
386:
143:
293:
242:The Phase IIb randomized, double-blind
18:
318:
316:
314:
312:
7:
299:
297:
280:, a treatment for AML marketed by
14:
185:. The drug had been developed by
1416:Monoclonal antibodies for tumors
323:Pollack A (September 13, 2010).
1411:Drugs not assigned an ATC code
1:
179:humanized monoclonal antibody
375:Journal of Clinical Oncology
344:Staff (September 13, 2010).
225:Food and Drug Administration
325:"Leukemia Drug Trial Fails"
199:myeloproliferative diseases
1437:
1361:
943:Mirvetuximab soravtansine
229:European Medicines Agency
213:myelodysplastic syndromes
181:used in the treatment of
154:
1339:Depatuxizumab mafodotin
1280:Tucotuzumab celmoleukin
1231:Rovalpituzumab tesirine
1146:Lorvotuzumab mertansine
1036:Clivatuzumab tetraxetan
388:10.1200/JCO.2005.09.133
231:had granted lintuzumab
1300:Vorsetuzumab mafodotin
1256:Tacatuzumab tetraxetan
1061:Denintuzumab mafodotin
1006:Bivatuzumab mertansine
933:Loncastuximab tesirine
923:Indatuximab ravtansine
800:Naptumomab estafenatox
191:acute myeloid leukemia
1285:Vandortuzumab vedotin
1236:Sacituzumab govitecan
1126:Inotuzumab ozogamicin
1111:Gemtuzumab ozogamicin
1041:Cofetuzumab pelidotin
1021:Cantuzumab ravtansine
1016:Cantuzumab mertansine
835:Nofetumomab merpentan
795:Moxetumomab pasudotox
549:Glembatumumab vedotin
435:Monoclonal antibodies
268:Gemtuzumab ozogamicin
219:History of AML trials
1332:Chimeric + humanized
1136:Lifastuzumab vedotin
996:Belantamab mafodotin
765:Ibritumomab tiuxetan
730:Anatumomab mafenatox
1251:Sofituzumab vedotin
1221:Polatuzumab vedotin
1216:Pinatuzumab vedotin
1201:Oportuzumab monatox
1031:Citatuzumab bogatox
893:Derlotuximab biotin
878:Brentuximab vedotin
830:Taplitumomab paptox
820:Satumomab pendetide
790:Nacolomab tafenatox
725:Altumomab pentetate
304:Lintuzumab (SGN-33)
189:as a treatment for
28:Monoclonal antibody
23:
1388:Never to phase III
750:Capromab pendetide
524:Enfortumab vedotin
330:The New York Times
257:blood transfusions
1398:
1397:
1357:
1356:
679:Tisotumab vedotin
172:
171:
16:Chemical compound
1428:
1310:Rat/mouse hybrid
449:
428:
421:
414:
405:
400:
390:
356:
355:
341:
335:
334:
320:
307:
301:
187:Seattle Genetics
168:
167:
160:
147:
111:
24:
22:
1436:
1435:
1431:
1430:
1429:
1427:
1426:
1425:
1401:
1400:
1399:
1394:
1393:
1378:Clinical trials
1353:
1327:
1304:
967:
854:
708:
438:
432:
368:
365:
360:
359:
343:
342:
338:
322:
321:
310:
302:
295:
290:
265:
221:
163:
161:
158:(what is this?)
155:
150:
130:
114:
89:
17:
12:
11:
5:
1434:
1432:
1424:
1423:
1418:
1413:
1403:
1402:
1396:
1395:
1392:
1391:
1390:
1389:
1386:
1375:
1369:
1363:
1362:
1359:
1358:
1355:
1354:
1352:
1351:
1346:
1344:Duvortuxizumab
1341:
1335:
1333:
1329:
1328:
1326:
1325:
1320:
1314:
1312:
1306:
1305:
1303:
1302:
1297:
1292:
1287:
1282:
1277:
1263:
1258:
1253:
1248:
1243:
1238:
1233:
1228:
1223:
1218:
1213:
1208:
1203:
1198:
1193:
1188:
1183:
1178:
1173:
1168:
1163:
1158:
1153:
1148:
1143:
1138:
1133:
1128:
1123:
1118:
1113:
1108:
1103:
1098:
1093:
1088:
1083:
1078:
1073:
1068:
1063:
1058:
1053:
1048:
1043:
1038:
1033:
1028:
1023:
1018:
1013:
1011:Brontictuzumab
1008:
1003:
998:
993:
988:
983:
977:
975:
969:
968:
966:
965:
960:
955:
950:
945:
940:
935:
930:
925:
920:
915:
910:
905:
900:
895:
890:
885:
880:
875:
870:
864:
862:
856:
855:
853:
852:
847:
842:
837:
832:
827:
822:
817:
812:
807:
802:
797:
792:
787:
782:
777:
772:
767:
762:
757:
752:
747:
742:
737:
732:
727:
722:
716:
714:
710:
709:
707:
706:
701:
696:
691:
686:
681:
676:
671:
666:
661:
656:
651:
646:
641:
636:
631:
626:
621:
616:
611:
606:
601:
596:
591:
586:
581:
576:
571:
566:
561:
556:
551:
546:
541:
536:
531:
526:
521:
516:
511:
506:
501:
496:
491:
486:
481:
478:+hyaluronidase
471:
466:
461:
455:
453:
446:
440:
439:
433:
431:
430:
423:
416:
408:
402:
401:
381:(18): 4110–6.
364:
361:
358:
357:
336:
308:
292:
291:
289:
286:
264:
261:
244:clinical trial
220:
217:
177:(SGN-33) is a
170:
169:
152:
151:
149:
148:
140:
138:
132:
131:
129:
128:
124:
122:
116:
115:
113:
112:
104:
102:
96:
95:
91:
90:
88:
87:
83:
81:
75:
74:
70:
69:
64:
58:
57:
47:
41:
40:
39:Whole antibody
37:
31:
30:
15:
13:
10:
9:
6:
4:
3:
2:
1433:
1422:
1419:
1417:
1414:
1412:
1409:
1408:
1406:
1387:
1385:
1382:
1381:
1379:
1376:
1373:
1370:
1368:
1365:
1364:
1360:
1350:
1347:
1345:
1342:
1340:
1337:
1336:
1334:
1330:
1324:
1321:
1319:
1316:
1315:
1313:
1311:
1307:
1301:
1298:
1296:
1293:
1291:
1288:
1286:
1283:
1281:
1278:
1275:
1271:
1267:
1264:
1262:
1259:
1257:
1254:
1252:
1249:
1247:
1244:
1242:
1239:
1237:
1234:
1232:
1229:
1227:
1226:Rosmantuzumab
1224:
1222:
1219:
1217:
1214:
1212:
1209:
1207:
1204:
1202:
1199:
1197:
1194:
1192:
1189:
1187:
1184:
1182:
1179:
1177:
1174:
1172:
1169:
1167:
1164:
1162:
1159:
1157:
1154:
1152:
1149:
1147:
1144:
1142:
1139:
1137:
1134:
1132:
1129:
1127:
1124:
1122:
1119:
1117:
1114:
1112:
1109:
1107:
1104:
1102:
1099:
1097:
1094:
1092:
1089:
1087:
1084:
1082:
1081:Enoblituzumab
1079:
1077:
1074:
1072:
1069:
1067:
1064:
1062:
1059:
1057:
1054:
1052:
1049:
1047:
1044:
1042:
1039:
1037:
1034:
1032:
1029:
1027:
1024:
1022:
1019:
1017:
1014:
1012:
1009:
1007:
1004:
1002:
999:
997:
994:
992:
989:
987:
984:
982:
979:
978:
976:
974:
970:
964:
961:
959:
956:
954:
951:
949:
946:
944:
941:
939:
936:
934:
931:
929:
926:
924:
921:
919:
916:
914:
911:
909:
906:
904:
901:
899:
896:
894:
891:
889:
886:
884:
881:
879:
876:
874:
871:
869:
866:
865:
863:
861:
857:
851:
848:
846:
843:
841:
838:
836:
833:
831:
828:
826:
823:
821:
818:
816:
813:
811:
808:
806:
803:
801:
798:
796:
793:
791:
788:
786:
783:
781:
778:
776:
773:
771:
768:
766:
763:
761:
758:
756:
753:
751:
748:
746:
743:
741:
738:
736:
733:
731:
728:
726:
723:
721:
718:
717:
715:
711:
705:
702:
700:
697:
695:
692:
690:
687:
685:
682:
680:
677:
675:
672:
670:
667:
665:
662:
660:
657:
655:
652:
650:
647:
645:
642:
640:
637:
635:
634:Pembrolizumab
632:
630:
627:
625:
622:
620:
617:
615:
612:
610:
607:
605:
602:
600:
597:
595:
592:
590:
587:
585:
582:
580:
577:
575:
572:
570:
567:
565:
562:
560:
557:
555:
552:
550:
547:
545:
542:
540:
537:
535:
532:
530:
527:
525:
522:
520:
517:
515:
512:
510:
507:
505:
502:
500:
497:
495:
492:
490:
487:
485:
482:
479:
475:
472:
470:
469:Ascrinvacumab
467:
465:
462:
460:
457:
456:
454:
450:
447:
445:
441:
436:
429:
424:
422:
417:
415:
410:
409:
406:
398:
394:
389:
384:
380:
376:
372:
367:
366:
362:
353:
352:
347:
340:
337:
332:
331:
326:
319:
317:
315:
313:
309:
305:
300:
298:
294:
287:
285:
283:
279:
275:
273:
269:
262:
260:
258:
254:
250:
245:
240:
238:
237:PDL BioPharma
234:
230:
226:
218:
216:
214:
210:
205:
202:
200:
196:
192:
188:
184:
180:
176:
166:
159:
153:
146:
142:
141:
139:
137:
133:
126:
125:
123:
121:
117:
110:
106:
105:
103:
101:
97:
92:
85:
84:
82:
80:
76:
73:Clinical data
71:
68:
65:
63:
59:
55:
51:
48:
46:
42:
38:
36:
32:
29:
25:
1421:Orphan drugs
1241:Sibrotuzumab
1206:Parsatuzumab
1191:Otlertuzumab
1186:Odronextamab
1181:Ocaratuzumab
1176:Obinutuzumab
1151:Lumretuzumab
1140:
1106:Flotetuzumab
1101:Ficlatuzumab
1096:Farletuzumab
1091:Etaracizumab
1076:Emibetuzumab
963:Zolbetuximab
938:Margetuximab
918:Girentuximab
780:Minretumomab
745:Blinatumomab
684:Teprotumumab
664:Seribantumab
489:Botensilimab
474:Atezolizumab
459:Adecatumumab
378:
374:
349:
339:
328:
276:
266:
241:
222:
206:
203:
174:
173:
162:
156:
1374:from market
1349:Ontuxizumab
1323:Ertumaxomab
1318:Catumaxomab
1290:Vanucizumab
1270:+deruxtecan
1266:Trastuzumab
1261:Tigatuzumab
1196:Onartuzumab
1171:Nimotuzumab
1161:Milatuzumab
1131:Labetuzumab
1121:Imgatuzumab
1086:Epcoritamab
1071:Emactuzumab
1056:Dalotuzumab
1046:Dacetuzumab
1026:Cirmtuzumab
1001:Bevacizumab
986:Alemtuzumab
958:Ublituximab
908:Ensituximab
903:Ecromeximab
898:Dinutuximab
883:Carotuximab
873:Bavituximab
850:Tositumomab
845:Tenatumomab
815:Racotumomab
760:Edrecolomab
735:Arcitumomab
704:Zalutumumab
694:Vantictumab
669:Sugemalimab
659:Robatumumab
654:Rilotumumab
649:Ramucirumab
624:Panitumumab
599:Necitumumab
589:Mapatumumab
584:Lucatumumab
579:Lexatumumab
569:Istiratumab
554:Intetumumab
539:Flanvotumab
534:Figitumumab
519:Dusigitumab
514:Duligotumab
504:Daratumumab
499:Conatumumab
494:Cixutumumab
484:Balstilimab
464:Amivantamab
278:Clofarabine
263:Competition
233:orphan drug
109:166089-32-3
94:Identifiers
1405:Categories
1295:Veltuzumab
1274:+emtansine
1246:Simtuzumab
1211:Pertuzumab
1141:Lintuzumab
1116:Glofitamab
1066:Elotuzumab
1051:Demcizumab
991:Axatilimab
981:Abituzumab
953:Siltuximab
928:Isatuximab
868:Amatuximab
840:Pintumomab
810:Pemtumomab
805:Oregovomab
740:Bectumomab
720:Abagovomab
674:Tarextumab
644:Radretumab
639:Pritumumab
629:Patritumab
619:Olaratumab
614:Ofatumumab
604:Nesvacumab
594:Narnatumab
564:Iratumumab
559:Ipilimumab
529:Enoticumab
509:Drozitumab
437:for tumors
288:References
249:cytarabine
209:bortezomib
175:Lintuzumab
145:V00Y10W60W
120:ChemSpider
100:CAS Number
21:Lintuzumab
1384:Phase III
1372:Withdrawn
1166:Naxitamab
1156:Matuzumab
973:Humanized
948:Rituximab
913:Futuximab
888:Cetuximab
825:Solitomab
785:Mitumomab
775:Lilotomab
755:Detumomab
699:Votumumab
689:Tovetumab
609:Nivolumab
574:Icrucumab
544:Ganitumab
50:Humanized
860:Chimeric
770:Igovomab
397:15961759
227:and the
165:(verify)
79:ATC code
363:Sources
282:Genzyme
253:placebo
1367:WHO-EM
395:
272:Pfizer
183:cancer
62:Target
52:(from
45:Source
713:Mouse
452:Human
444:Tumor
54:mouse
393:PMID
195:CD33
136:UNII
127:none
86:none
67:CD33
35:Type
383:doi
1407::
1380::
1272:/
391:.
379:23
377:.
373:.
348:.
327:.
311:^
296:^
259:.
215:.
1276:)
1268:(
480:)
476:(
427:e
420:t
413:v
399:.
385::
354:.
333:.
56:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.